Announced Date: 2025-11-03 (November 3, 2025) Licensor (Seller): TransThera Sciences (China) Licensee (Buyer): Neurocrine Biosciences (US) … [China BD 2025] TransThera and Neurocrine Enters a 882 USD Million License on NLRP3 Inhibitor ProgramRead more
Author: admin
China NMPA Approved New Drugs (Biological Products) ADC
Updated in 2025-10 . ADC Target Drug Name Code Approved Time Company Partner ADC Design HER2 … China NMPA Approved New Drugs (Biological Products) ADCRead more
[China BD 2025] Minwei Biotech (Lepu) and Sidera Bio Enters a 1 Billion USD License for GLP-1/GIP/FGF21 Agonist Peptides MWN105
Announced Date: 2025-10-31 (October 31, 2025) Asset Name: MWN105 Licensor (Seller): Shanghai Minwei Biotech, subsidiary of … [China BD 2025] Minwei Biotech (Lepu) and Sidera Bio Enters a 1 Billion USD License for GLP-1/GIP/FGF21 Agonist Peptides MWN105Read more
[China BD 2025] Qyuns Therapeutics and Roche Entered a 107 Million USD License for TSLP/IL-33 Bispecific Antibody QX031N
Announced Date: 2025-10-28 (October 28, 2025) Asset Name: QX031N Licensor (Seller): Qyuns Therapeutics (China) Licensee (Buyer): … [China BD 2025] Qyuns Therapeutics and Roche Entered a 107 Million USD License for TSLP/IL-33 Bispecific Antibody QX031NRead more
[China BD 2025] Innovent Biologics and Takada enters 11.4 Billion USD License and Collaboration Agreement on Three Oncology Assets, IBI363 (PD-1/IL-2α-bias), IBI343 (CLDN18.2 ADC) and IBI3001 (EGFR/B7H3 ADC)
Announced Date: 2025-10-21 (October 21, 2025) Asset Name: IBI363 (PD-1/IL-2α-bias), IBI343 (CLDN18.2 ADC)，IBI3001 (EGFR/B7H3 ADC) Licensor … [China BD 2025] Innovent Biologics and Takada enters 11.4 Billion USD License and Collaboration Agreement on Three Oncology Assets, IBI363 (PD-1/IL-2α-bias), IBI343 (CLDN18.2 ADC) and IBI3001 (EGFR/B7H3 ADC)Read more
[China BD 2025] Pregene Biopharma and KitePharma (Gliead) enters a 1.64 Billion USD License on In vivo CAR-T
Announced Date: 2025-10-16 (October 16, 2025) Licensor (Seller): Pregene Biopharma (China) Licensee (Buyer): KitePharma (Gliead) . … [China BD 2025] Pregene Biopharma and KitePharma (Gliead) enters a 1.64 Billion USD License on In vivo CAR-TRead more
[China BD 2025] Hansoh and Roche enters a 1.53 Billion USD License on CDH17 ADC HS-20110
Announced Date: 2025-10-17 (October 17, 2025) Licensor (Seller): Hansoh Pharma (China) Licensee (Buyer): Roche . Asset … [China BD 2025] Hansoh and Roche enters a 1.53 Billion USD License on CDH17 ADC HS-20110Read more
[China BD 2025] Leads Biolabs and Dianthus enters a 1 Billion USD License on DNTH212 (LBL-047), a bifunctional BDCA2 and BAFF/APRIL inhibitor
Announced Date: 2025-10-16 (October 16, 2025) Licensor (Seller): Nanjing Leads Biolabs (China) Licensee (Buyer): Dianthus Therapeutics … [China BD 2025] Leads Biolabs and Dianthus enters a 1 Billion USD License on DNTH212 (LBL-047), a bifunctional BDCA2 and BAFF/APRIL inhibitorRead more
[China BD 2025] Haihe Biopharma and Taiho Pharmaceutical enters a License on PI3Kα Inhibitor Risovalisib (CYH33)
Announced Date: 2025-10-16 (October 16, 2025) Licensor (Seller): HaiHe Biopharma (China) Licensee (Buyer): Taiho Pharmaceutical (JP) … [China BD 2025] Haihe Biopharma and Taiho Pharmaceutical enters a License on PI3Kα Inhibitor Risovalisib (CYH33)Read more
[China BD 2025] InnoCare Pharma and Zenas BioPharma enters 2 Billion USD License on Three Autoimmune Product Candidates
Announced Date: 2025-10-08 (October 8, 2025) Asset Name: BTK inhibitor Orelabrutinib; Oral IL-17AA/AF inhibitor; Oral TYK2 … [China BD 2025] InnoCare Pharma and Zenas BioPharma enters 2 Billion USD License on Three Autoimmune Product CandidatesRead more